

Survey on chronic spontaneous urticaria: a worldwide perspective

1 Your country of residence:

- | | | |
|---|--|--|
| <input type="radio"/> Afghanistan | <input type="radio"/> Costa Rica | <input type="radio"/> Italy |
| <input type="radio"/> Algeria | <input type="radio"/> Côte d'Ivoire | <input type="radio"/> Jamaica |
| <input type="radio"/> American Samoa | <input type="radio"/> Croatia | <input type="radio"/> Japan |
| <input type="radio"/> Andorra | <input type="radio"/> Cuba | <input type="radio"/> Jordan |
| <input type="radio"/> Angola | <input type="radio"/> Cyprus | <input type="radio"/> Kazakhstan |
| <input type="radio"/> Antigua and Barbuda | <input type="radio"/> Czech Republic | <input type="radio"/> Kenya |
| <input type="radio"/> Argentina | <input type="radio"/> Denmark | <input type="radio"/> Kiribati |
| <input type="radio"/> Armenia | <input type="radio"/> Djibouti | <input type="radio"/> North Korea |
| <input type="radio"/> Australia | <input type="radio"/> Dominica | <input type="radio"/> South Korea |
| <input type="radio"/> Austria | <input type="radio"/> Dominican Republic | <input type="radio"/> Kosovo |
| <input type="radio"/> Azerbaijan | <input type="radio"/> East Timor | <input type="radio"/> Kuwait |
| <input type="radio"/> Bahamas | <input type="radio"/> Ecuador | <input type="radio"/> Kyrgyzstan |
| <input type="radio"/> Bahrain | <input type="radio"/> Egypt | <input type="radio"/> Laos |
| <input type="radio"/> Bangladesh | <input type="radio"/> El Salvador | <input type="radio"/> Latvia |
| <input type="radio"/> Barbados | <input type="radio"/> Equatorial Guinea | <input type="radio"/> Lebanon |
| <input type="radio"/> Belarus | <input type="radio"/> Eritrea | <input type="radio"/> Lesotho |
| <input type="radio"/> Belgium | <input type="radio"/> Estonia | <input type="radio"/> Liberia |
| <input type="radio"/> Belize | <input type="radio"/> Ethiopia | <input type="radio"/> Libya |
| <input type="radio"/> Benin | <input type="radio"/> Faroe Islands | <input type="radio"/> Liechtenstein |
| <input type="radio"/> Bermuda | <input type="radio"/> Fiji | <input type="radio"/> Lithuania |
| <input type="radio"/> Bhutan | <input type="radio"/> Finland | <input type="radio"/> Luxembourg |
| <input type="radio"/> Bolivia | <input type="radio"/> France | <input type="radio"/> Macedonia |
| <input type="radio"/> Bosnia and Herzegovina | <input type="radio"/> French Polynesia | <input type="radio"/> Madagascar |
| <input type="radio"/> Botswana | <input type="radio"/> Gabon | <input type="radio"/> Malawi |
| <input type="radio"/> Brazil | <input type="radio"/> Gambia | <input type="radio"/> Malaysia |
| <input type="radio"/> Brunei | <input type="radio"/> Georgia | <input type="radio"/> Maldives |
| <input type="radio"/> Bulgaria | <input type="radio"/> Germany | <input type="radio"/> Mali |
| <input type="radio"/> Burkina Faso | <input type="radio"/> Ghana | <input type="radio"/> Malta |
| <input type="radio"/> Burundi | <input type="radio"/> Greece | <input type="radio"/> Marshall Islands |
| <input type="radio"/> Cambodia | <input type="radio"/> Greenland | <input type="radio"/> Mauritania |
| <input type="radio"/> Cameroon | <input type="radio"/> Grenada | <input type="radio"/> Mauritius |
| <input type="radio"/> Canada | <input type="radio"/> Guam | <input type="radio"/> Mexico |
| <input type="radio"/> Cape Verde | <input type="radio"/> Guatemala | <input type="radio"/> Micronesia |
| <input type="radio"/> Cayman Islands | <input type="radio"/> Guinea | <input type="radio"/> Moldova |
| <input type="radio"/> Central African Republic | <input type="radio"/> Guinea-Bissau | <input type="radio"/> Monaco |
| <input type="radio"/> Chad | <input type="radio"/> Guyana | <input type="radio"/> Mongolia |
| <input type="radio"/> Chile | <input type="radio"/> Haiti | <input type="radio"/> Montenegro |
| <input type="radio"/> China | <input type="radio"/> Honduras | <input type="radio"/> Morocco |
| <input type="radio"/> Colombia | <input type="radio"/> Hong Kong | <input type="radio"/> Mozambique |
| <input type="radio"/> Comoros | <input type="radio"/> Hungary | <input type="radio"/> Myanmar |
| <input type="radio"/> Congo, Democratic Republic of the | <input type="radio"/> Iceland | <input type="radio"/> Namibia |
| <input type="radio"/> Congo, Republic of the | <input type="radio"/> India | <input type="radio"/> Nauru |
| | <input type="radio"/> Indonesia | <input type="radio"/> Nepal |
| | <input type="radio"/> Iran | <input type="radio"/> Netherlands |
| | <input type="radio"/> Iraq | <input type="radio"/> New Zealand |
| | <input type="radio"/> Ireland | <input type="radio"/> Nicaragua |
| | <input type="radio"/> Israel | <input type="radio"/> Niger |
| | | <input type="radio"/> Nigeria |

- | | | |
|--|---|---|
| <input type="radio"/> Northern Mariana Islands | <input type="radio"/> Sao Tome and Principe | <input type="radio"/> Togo |
| <input type="radio"/> Norway | <input type="radio"/> Saudi Arabia | <input type="radio"/> Tonga |
| <input type="radio"/> Oman | <input type="radio"/> Senegal | <input type="radio"/> Trinidad and Tobago |
| <input type="radio"/> Pakistan | <input type="radio"/> Serbia | <input type="radio"/> Tunisia |
| <input type="radio"/> Palau | <input type="radio"/> Seychelles | <input type="radio"/> Turkey |
| <input type="radio"/> Palestine, State of | <input type="radio"/> Sierra Leone | <input type="radio"/> Turkmenistan |
| <input type="radio"/> Panama | <input type="radio"/> Singapore | <input type="radio"/> Tuvalu |
| <input type="radio"/> Papua New Guinea | <input type="radio"/> Sint Maarten | <input type="radio"/> Uganda |
| <input type="radio"/> Paraguay | <input type="radio"/> Slovakia | <input type="radio"/> Ukraine |
| <input type="radio"/> Peru | <input type="radio"/> Slovenia | <input type="radio"/> United Arab Emirates |
| <input type="radio"/> Philippines | <input type="radio"/> Solomon Islands | <input type="radio"/> United Kingdom |
| <input type="radio"/> Poland | <input type="radio"/> Somalia | <input type="radio"/> United States |
| <input type="radio"/> Portugal | <input type="radio"/> South Africa | <input type="radio"/> Uruguay |
| <input type="radio"/> Puerto Rico | <input type="radio"/> Spain | <input type="radio"/> Uzbekistan |
| <input type="radio"/> Qatar | <input type="radio"/> Sri Lanka | <input type="radio"/> Vanuatu |
| <input type="radio"/> Romania | <input type="radio"/> Sudan | <input type="radio"/> Vatican City |
| <input type="radio"/> Russia | <input type="radio"/> Sudan, South | <input type="radio"/> Venezuela |
| <input type="radio"/> Rwanda | <input type="radio"/> Suriname | <input type="radio"/> Vietnam |
| <input type="radio"/> Saint Kitts and Nevis | <input type="radio"/> Swaziland | <input type="radio"/> Virgin Islands, British |
| <input type="radio"/> Saint Lucia | <input type="radio"/> Sweden | <input type="radio"/> Virgin Islands, U.S. |
| <input type="radio"/> Saint Vincent and the Grenadines | <input type="radio"/> Switzerland | <input type="radio"/> Yemen |
| <input type="radio"/> Samoa | <input type="radio"/> Syria | <input type="radio"/> Zambia |
| <input type="radio"/> San Marino | <input type="radio"/> Taiwan | <input type="radio"/> Zimbabwe |
| | <input type="radio"/> Tajikistan | |
| | <input type="radio"/> Tanzania | |
| | <input type="radio"/> Thailand | |

2 Your gender:

- Female
 Male

3 Your age:

- Less than 30
 30-39
 40-49
 50-59
 60-69
 Greater than 69

4 Your specialty (Please choose all that apply):

- Allergy/Immunology
 Dermatology
 Paediatrics
 General practice
 Other: _____

5 Length of time in your current field of practice (years):

- Less than 5 years
- Between 5 and 9 years
- Between 10 and 14 years
- Between 15 and 19 years
- Over 19

6 You work at (Please choose all that apply):

- Private practice
- University clinic
- Hospital
- Specialized urticaria centre
- Other: _____

7 You primarily see:

- Outpatients
- Inpatients
- Other

8 You primarily see:

- Adults
- Children
- Both

9 How many Chronic Spontaneous Urticaria (CSU) patients do you see per week?

- 0-5
- 6-9
- 10-20
- 21-30
- 31-40
- 41-50
- >50
- Other (please specify)

10 How often do your CSU patients complain of angioedema? (% from the total number of patients)

- Less than 10%
- 10-20%
- 21-30%
- 31-40%
- 41-50%

- 51-60%
- 61-70%
- 71-80%
- 81-90%
- Over 90%

11 Please specify the urticaria guidelines you are aware of (Please choose **all** that apply):

- EAACI/WAO/GA2LEN/EDF
- AAAAI practice parameter
- National guidelines
- I am not aware of any
- Other: _____

12 Which of the guidelines do you follow in clinical practice (Please choose **all** that apply):

- EAACI/WAO/GA2LEN/EDF
- AAAAI practice parameter
- National guidelines
- I don't use any
- Other: _____

13 If you DO NOT FOLLOW OR DEVIATE from the guidelines, please indicate the reasons behind it (Please choose **all** that apply):

- The guidelines do not undergo revision frequently enough
- I rely more on my own clinical experience
- I do not agree with the guidelines' recommendations and/or conclusions
- Some of the recommendations are unclear to me and require further detailization
- Some of the guidelines' recommendations cannot be implicated in my country of residence
- I had a negative experience with following the guidelines in my clinical practice
- Overly simplified approach to CSU management recommended by the guidelines that does not reflect the complexity of the disease
- The discrepancy and/or disagreement between the guidelines
- Not applicable
- Other: _____

14 Which of the following tests do you order or perform in all CSU patients? (Please choose **all** that apply):

- Complete blood count (CBC) with differential
- Erythrocyte sedimentation rate (ESR)
- C-reactive protein (CRP)
- Anti-thyroid antibodies (anti-TG/TPO)
- Thyroid stimulating hormone (TSH)

- Total IgE
- Eosinophil cationic protein (ECP)
- D-dimer
- Skin prick tests
- Allergen-specific IgE
- Antinuclear antibodies (ANA)
- Tryptase
- Autologous serum skin test (ASST)
- Search for chronic infections
- None
- Other: _____

15 Which of the following tests do you order or perform in patients with long-standing (>6 months), severe (symptoms interfering with normal daily activity and sleep) and poorly-controlled disease (lack of response to antihistamines)? (Check any that apply in addition to those selected in previous question):

- CBC with differential
- ESR
- CRP
- Anti-thyroid antibodies (anti-TG/TPO)
- TSH
- Total IgE
- ECP
- D-dimer
- Skin prick tests
- Allergen-specific IgE
- ANA
- Tryptase
- ASST
- Search for chronic infections
- None
- Other: _____

16 How often do you elucidate a cause of CSU, %? (Note: the cause of CSU is the condition that when treated leads to improvement or resolution of CSU):

- Less than 10%
- 10-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71-80%
- 81-90%
- Over 90%

17 What are the common etiologies of CSU in your patients? (Please rank the frequency of CSU causes from 1 to 8: the most common cause - 1, the least common - 8)

- Idiopathic
- Type-I-Allergy
- Autoimmunity/autoreactivity
- Underlying systemic disorders
- Malignancy
- Chronic infections
- Food intolerance
- Non-neoplasm underlying systemic disorder
- Others

18 Which of the following medications do you administer a CSU patient as a first-line treatment? (Multiple answers will be regarded as a combination of medications used in the same patient):

- First-generation H1-antihistamines
- Second-generation H1-antihistamines at standard dose
- Updosed second-generation H1-antihistamines (2-4 times the standard dose)
- H2-antihistamines (e.g. famotidine or ranitidine)
- Ciclosporin
- Omalizumab
- Montelukast
- Dapsone
- Systemic corticosteroids (for less than 10 days)
- Systemic corticosteroids (for more than 10 days in a row)
- Other: _____

19 Which of the following medications do you administer a CSU patient as a second-line treatment? (Multiple answers will be regarded as a combination of medications used in the same patient. Answer this question independently from question #18):

- First-generation H1-antihistamines
- Second-generation H1-antihistamines at standard dose
- Updosed second-generation H1-antihistamines (2-4 times the standard dose)
- H2-antihistamines (e.g. famotidine or ranitidine)
- Ciclosporin
- Omalizumab
- Montelukast
- Dapsone
- Systemic corticosteroids (for less than 10 days)
- Systemic corticosteroids (for more than 10 days in a row)
- Other: _____

20 Which of the following medications do you administer a CSU patient as a third-line treatment? (Multiple answers will be regarded as a combination of medications used in the same patient. Answer this question independently from questions #18, 19):

- First-generation H1-antihistamines
- Second-generation H1-antihistamines at standard dose
- Updosed second-generation H1-antihistamines (2-4 times the standard dose)
- H2-antihistamines (e.g. famotidine or ranitidine)
- Ciclosporin
- Omalizumab
- Montelukast
- Dapsone
- Systemic corticosteroids (for less than 10 days)
- Systemic corticosteroids (for more than 10 days in a row)
- Other: _____

21 Please indicate your opinion on the overall efficacy of the following agents in treatment of CSU. Please choose the appropriate response for each item:

	Very high	High	Moderate	Low	Not effective
H1-antihistamines of first generation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H1-antihistamines of second generation in standard dose	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H1-antihistamines of second generation in high doses (2-4 times higher)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H2-antihistamines (e.g. famotidine or ranitidine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ciclosporin	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Omalizumab	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Montelukast	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Dapsone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic corticosteroids (for less than	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very high	High	Moderate	Low	Not effective
10 days) Systemic corticosteroids (for more than 10 days in a row)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

22 Please assess tolerability of the following agents in treatment of CSU. Please choose the appropriate response for each item:

	Good	Moderate	Bad
H1-antihistamines of first generation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H1-antihistamines of second generation in standard dose	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H1-antihistamines of second generation in high doses (2-4 times higher)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
H2-antihistamines (e.g. famotidine or ranitidine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ciclosporin	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Omalizumab	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Montelukast	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Dapsone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic corticosteroids (for less than 10 days)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic corticosteroids (for more than 10 days in a row)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

23 Do you record data from CSU patients?

- No
- Yes - Own database
- Yes - Hospital/Intitution's database
- Yes - National registry
- Yes - Registry organized by a Allergy or Dermatology medical society
- Yes - Other

24 Have you ever heard of the possibility to enter patient data into the chronic urticaria registry (CURE) for scientific analyses (www.urticaria-registry.com)?

Please choose **only one** of the following:

- Yes
- No

Thank you for taking your time to participate in our survey! If there are any comments or suggestions please enter them below.

Please write your answer here:

Thank you very much for your participation!